B.C. approves one-time funding for North Vancouver boy's rare disease treatment in Germany The B.C. government has agreed to provide up to $400,000 for Nathan Hepburn's remaining treatment for a rare brain arteriovenous malformation, reversing an earlier denial after appeals from his medical team and family advocacy. The British Columbia government has agreed to provide one-time financial support for a North Vancouver boy with a rare and potentially fatal brain condition to receive treatment in Germany, after months of advocacy by his family and renewed scrutiny of how the province handles extraordinary medical cases. Nathan Hepburn was diagnosed with an extremely rare brain arteriovenous malformation, known as an AVM, a vascular abnormality that can carry the risk of severe brain bleeding or hemorrhage. His mother, Natasha Hepburn, said there was no cure available in North America for Nathan's specific condition. Through research and outreach to specialists abroad, she identified a physician in Germany who had pioneered a treatment approach for this type of case.The family first turned to public support, raising about $195,000 through a GoFundMe campaign to help cover the cost and logistics of pursuing care overseas. After continued advocacy, the provincial government agreed to step in with up to $400,000 in funding.In a letter sent to Natasha Hepburn, then-B.C. health minister Ravi Kahlon acknowledged the family's tireless efforts and said the government recognized that medical care is evolving and that families facing serious, complex illnesses may look for innovative treatment options when they are seeking the best possible outcome for a loved one. The approval was described as exceptional and one-time, meaning it was granted for the specific medical costs connected with Nathan's remaining AVM treatments rather than as a broad precedent for similar cases.The funding does not cover travel, lodging, meals, or other non-medical expenses. The decision marks a reversal from an earlier position in which the treatment was rejected as experimental. That denial was appealed in May by Nathan's local neurology team, who supported pursuing the overseas option. Natasha Hepburn said receiving the letter brought together gratitude, relief and disbelief.Political Timing Of Decision QuestionedShe said she does not understand why the funding was initially denied, but she will never forget the impact of the delay on a family trying to protect a child's life. She also noted that Kahlon made the decision while still serving as health minister, shortly before he said privately that his final days in cabinet were coming to an end. The timing of the funding has raised questions among political opponents. Former B.C.Conservative health critic Anna Kindy, who has also advocated for the Hepburn family, said she is pleased the decision was eventually made, but she questioned whether the timing suggests a political motivation or a genuine response to the medical evidence. Kindy also asked whether the next family facing a rare condition will receive the same level of support, especially if they do not have advocates willing and able to push the issue.Systemic Issues Facing Rare Disease FamiliesKindy argued that vulnerable patients can fall through the cracks when the health system is under pressure and when treatment options are rare, expensive, or not clearly covered by public funding. Her comments reflected broader concern that families may need to rely on fundraising, media attention, or political pressure to access care that doctors believe could be life-saving.For Natasha Hepburn, the approval means Nathan may have a chance to continue moving forward and reduce the fear that his condition could suddenly become fatal. She thanked those who supported the campaign and those in government who ultimately helped make the treatment possible. The case has renewed debate in B.C. about how the province should respond when a child has a rare disease, when standard treatments are unavailable, and when families are forced to search beyond Canada for hope.